Accession Number:

AD1007533

Title:

In Vitro Endocrine Disruption Screening of 3-nitro-1,2,4-triazol-5-one (NTO)

Descriptive Note:

Technical Report,01 Sep 2011,30 Sep 2012

Corporate Author:

US Army Public Health Command Aberdeen Proving Ground United States

Personal Author(s):

Report Date:

2012-09-25

Pagination or Media Count:

40.0

Abstract:

The compound, 5-nitro-1,2,4-triazol-3-one, NTO is an explosive that performs similar to RDX but has reduced sensitivity compared to RDX. Routine safety assessments including toxicity testing have been performed with NTO. NTO has been demonstrated to affect testes weights in orally dosed rats. One possible mode of action for adverse testicular effects is hormonal endocrine disregulation. A series of in vitro bioassays were performed to assess if NTO disrupts the endocrinesystem. The assays performed were estrogen receptor binding, androgen receptor binding, estrogen transactivation, aromatase, and steroidogenesis. The endpoints of these assays contribute to a weight of evidence WoE strategy for determining NTO endocrine disruption. No NTO effects on the tested in vitro endpoints were observed and using a WoE approach, NTO does not appear to directly affect testosterone or estrogen mediated endocrine regulation.

Subject Categories:

Distribution Statement:

APPROVED FOR PUBLIC RELEASE